Market brief
Swiss Biotech & Pharma Landscape 2026: Basel, Lausanne, Zurich
Switzerland holds 36 operators in the directory, concentrated heavily in Basel (12) with Lausanne (3), Schlieren (3), Bubendorf (2), Allschwil (2), Plan-les-Ouates (2), Geneva (2), and smaller single-operator sites. Roche and Novartis in Basel are the two dominant pharma anchors — both running global commercial pharma with broad oncology, rare-disease, neuroscience, and biologics pipelines. The Swiss CDMO layer includes Lonza (Visp) for large-scale biologics + ADC, Bachem (Bubendorf) for peptide and oligonucleotide API, Siegfried (Zofingen) for small-molecule CDMO, CARBOGEN AMCIS (Bubendorf) for ADC + specialty, and Celonic (Basel) for biologics process development. Clinical-stage therapeutics cluster in Basel (Basilea, BioVersys, Alentis, Anaveon, Noema Pharma, Cimeio, Myria, ARTIDIS), Allschwil (Idorsia, Engimmune), Lausanne (Debiopharm, AB2 Bio, SUN bioscience), and Zurich-adjacent Schlieren (Biognosys, InSphero, Memo Therapeutics). Geneva adds ADC Therapeutics (Epalinges) and KBI Biopharma Geneva CDMO. Switzerland operates outside the EU but uses GDP-aligned logistics and EMA-integrated regulatory pathways.
Summary
Key findings
Basel holds 12 operators — the densest Swiss biotech city in the directory — anchored by Roche and Novartis as the two dominant pharma operators, with Basilea, BioVersys, Alentis, Anaveon, Cimeio, Noema Pharma, and ARTIDIS as adjacent clinical-stage therapeutics and diagnostics.
The Swiss CDMO layer holds seven operators the directory surfaces: Lonza Visp (large biologics + ADC), Bachem Bubendorf (peptide + oligonucleotide API), Siegfried Zofingen (small-molecule CDMO), CARBOGEN AMCIS Bubendorf (ADC + specialty), Celonic Basel (biologics process development), KBI Biopharma Geneva (biologics CDMO), and Cerbios-Pharma Barbengo (ADC + HPAPI).
The Lemanic Arc (Lausanne + Geneva + Allschwil cluster) holds clinical-stage therapeutics innovators — Debiopharm, AB2 Bio, SUN bioscience, ADC Therapeutics, Antion Biosciences, KBI Biopharma Geneva, Idorsia — with EPFL and the Swiss academic medical base as the research-layer anchor.
Schlieren (the Zurich-area Bio-Technopark Schlieren-Zürich) concentrates the German-speaking Swiss innovation cluster: Biognosys (proteomics tools), InSphero (3D tissue models), Memo Therapeutics. Ypsomed (Burgdorf) adds drug-delivery devices adjacent to the Zurich axis.
Numbers
Quick numbers
Analysis
Basel: the Swiss pharma anchor city
Basel concentrates 12 operators in the directory — the densest Swiss biotech city by directory count. Roche and Novartis are both headquartered in Basel and run global commercial pharma across oncology, rare-disease, neuroscience, and biologics. Sandoz, the former Novartis generics and biosimilars arm (independent since October 2023 when Novartis spun it out), is listed separately in the directory under Basel. Around the big-pharma anchors, Basel hosts a clinical-stage therapeutics layer: Basilea (antifungal + oncology therapeutics at commercial scope), BioVersys (anti-microbial drug discovery), Alentis Therapeutics (fibrosis + oncology antibodies), Anaveon (IL-2 immunotherapy), Cimeio Therapeutics (shielded cell therapy), Noema Pharma (CNS therapeutics), Myria Biosciences (early-stage biotech), and ARTIDIS (cancer nano-diagnostics). Celonic adds biologics process-development CDMO capacity within the Basel city limits. For sponsors running a European biotech search in 2026, Basel is the first-look entry point for Swiss big pharma, oncology + antimicrobial therapeutics, and biologics process development.
Analysis
Bubendorf + Visp + Zofingen: the Swiss CDMO and API backbone
The Swiss CDMO and API backbone sits outside Basel proper. Lonza (Visp) is the Swiss biologics + ADC + cell-and-gene-therapy CDMO the directory surfaces at global commercial scale. Bachem (Bubendorf) holds peptide and oligonucleotide API manufacturing at scale, supplying synthetic APIs into mRNA, ASO, peptide-conjugate, and peptide-drug programmes across Europe and the US. CARBOGEN AMCIS (also Bubendorf) runs ADC and specialty small-molecule + sterile fill-finish capacity. Siegfried (Zofingen) operates API + small-molecule CDMO services at commercial scale with a Swiss quality track record. Cerbios-Pharma (Barbengo, Ticino) specialises in ADC, highly potent APIs, and extraction. Celonic (Basel) adds biologics process-development CDMO. KBI Biopharma Geneva runs biologics CDMO services as part of the global KBI network. Octapharma (Lachen) operates plasma-derived therapeutics manufacturing alongside the CDMO layer. Together the seven CDMO operators plus Octapharma’s plasma-derived capacity form the Swiss CDMO + API backbone — the European CDMO Capacity 2026 brief covers the wider European landscape.
Analysis
Lausanne + Geneva + Allschwil: the Lemanic Arc cluster
The Lemanic Arc (French-speaking Switzerland plus adjacent Allschwil) hosts the Swiss clinical-stage therapeutics belt. Debiopharm (Lausanne) operates as a private Swiss pharma with oncology, rare-disease, and antibody pipelines. AB2 Bio (Lausanne) runs anti-inflammatory therapeutics. SUN bioscience (Lausanne) provides organoid and 3D-cell-culture tools for drug discovery. ADC Therapeutics (Epalinges, near Lausanne) develops antibody-drug conjugates at clinical scale. Idorsia (Allschwil, adjacent to Basel) runs CNS, sleep, and cardiovascular therapeutics with commercial-stage products. Engimmune Therapeutics (Allschwil) develops TCR-based cancer immunotherapies. Geneva hosts KBI Biopharma Geneva (biologics CDMO, part of the global KBI Biopharma network) and Antion Biosciences (allogeneic CAR-T + multiplex gene silencing). For sponsors, the Lemanic Arc is the Swiss French-speaking clinical-stage and API-adjacent cluster complementing Basel’s pharma-first gravity.
Analysis
Schlieren + Burgdorf + Bern: the Zurich-area + German-speaking cluster
Schlieren hosts the Bio-Technopark Schlieren-Zürich and concentrates the Zurich-area biotech cluster: Biognosys runs mass-spectrometry-based proteomics tools; InSphero develops 3D in-vitro tissue models and assay services; Memo Therapeutics develops antibody therapeutics. Burgdorf (central Switzerland) hosts Ypsomed, the Swiss drug-delivery device specialist (autoinjectors, pens, pumps) that partners with pharma manufacturers across Europe. Bern adds InnoMedica (oncology therapeutics). Together they form the Swiss German-speaking biotech layer complementing Basel and the Lemanic Arc — see the Schlieren city page for the Bio-Technopark detail.
Analysis
Switzerland’s role in the European biotech supply chain
Switzerland is not an EU member state but is operationally integrated into European pharmaceutical trade. It uses GDP-aligned pharmaceutical logistics through the same operators covering Germany and the Baltics (DHL Life Sciences & Healthcare, Kuehne+Nagel Healthcare, World Courier), ships under EU-compatible commercial terms, and interfaces with EMA through established pathways. Swissmedic runs the national regulatory authority. For sponsors, the one friction point is tri-lateral Swissmedic + EMA + FDA coordination where programmes target multiple regions — but this is routine for Swiss big pharma and their CDMO partners. The European mRNA & Immunotherapy 2026 brief, the European CDMO Capacity 2026 brief, and the Swiss vs German Biotech Manufacturing 2026 brief cover the cross-country decision logic in more detail.
Analysis
How to pick a Swiss biotech partner in 2026
Match the decision to the need. Big-pharma partnership or licensing: Roche or Novartis (the two dominant Basel anchors). Biosimilars + generics: Sandoz (Basel, independent Novartis spin-out since 2023). Large-scale biologics + ADC CDMO: Lonza (Visp). Peptide or oligonucleotide API: Bachem (Bubendorf). Small-molecule API CDMO: Siegfried (Zofingen). ADC and HPAPI specialty: CARBOGEN AMCIS (Bubendorf) or Cerbios-Pharma (Barbengo). Biologics process development + CDMO: Celonic (Basel) or KBI Biopharma Geneva. Plasma-derived therapeutics: Octapharma (Lachen). Drug-delivery devices: Ypsomed (Burgdorf). Clinical-stage oncology + rare-disease therapeutics: Basilea, Idorsia, Debiopharm, ADC Therapeutics. Proteomics and 3D-tissue tools: Biognosys or InSphero (Schlieren). The How to Pick a European Biotech Partner 2026 brief covers partner selection across the full directory.
What to watch
What to watch next
Roche and Novartis oncology + rare-disease pipeline disclosures
Lonza Visp capacity expansion and new commercial programmes
Bachem oligonucleotide capacity growth tied to mRNA and ASO demand
ADC Therapeutics ZYNLONTA (loncastuximab tesirine) commercial progression and pipeline ADCs
Idorsia commercial launches and partnership activity
Swiss-EU regulatory coordination under the EU Biotech Act implementation
FAQ
Frequently asked questions
Who are the main Swiss pharma companies?
Roche and Novartis, both headquartered in Basel, are the two dominant Swiss pharma anchors in the directory — running global commercial pharma across oncology, rare-disease, neuroscience, biologics, and ophthalmology. Sandoz (Basel) is the biosimilar and generics company Novartis spun out as an independent listed company in October 2023. Idorsia (Allschwil) runs CNS, sleep, and cardiovascular therapeutics at commercial scope. Basilea (Basel) operates antifungal + oncology therapeutics. Debiopharm (Lausanne) is a private Swiss pharma with oncology and rare-disease pipelines.
Where do I go for Swiss biologics or ADC CDMO?
Lonza (Visp) is the Swiss biologics + ADC + cell-and-gene-therapy CDMO anchor at commercial scale and one of the main European options for large-integrated biologics programmes. CARBOGEN AMCIS (Bubendorf) and Cerbios-Pharma (Barbengo) provide ADC + HPAPI specialty capacity. Celonic (Basel) provides biologics process development. KBI Biopharma Geneva runs biologics CDMO services as part of the global KBI network. The European CDMO Capacity 2026 brief covers the wider landscape and Swiss vs German Biotech Manufacturing 2026 has the decision rule.
What is Bachem known for?
Bachem (Bubendorf, Switzerland) operates peptide and oligonucleotide API manufacturing at scale, supplying synthetic APIs across mRNA programmes, antisense oligonucleotides (ASO), peptide-oligonucleotide conjugates, and peptide-drug programmes. It is one of the European options on the synthetic API side for sponsors combining Swiss API supply with EU biologics manufacturing downstream. The European mRNA & Immunotherapy 2026 brief covers the supply-chain context.
How does the Lemanic Arc cluster differ from Basel?
Basel is the Swiss pharma-capital anchor — Roche, Novartis, Sandoz plus a clinical-stage therapeutics layer and the Bubendorf CDMO belt. The Lemanic Arc (Lausanne + Geneva + Allschwil) is more French-speaking, more clinical-stage-innovator focused, and anchored to EPFL and the Swiss academic medical base rather than the big-pharma gravity. Debiopharm, AB2 Bio, SUN bioscience, ADC Therapeutics, Idorsia, Engimmune, KBI Biopharma Geneva, and Antion Biosciences sit in this geography.
Is Switzerland in the EU for pharmaceutical regulation?
No, but it is operationally integrated. Swissmedic is the national drug regulator, separate from EMA. Swiss manufacturers interface with EMA through established pathways, use GDP-compatible logistics with the rest of Europe, and ship under EU-aligned commercial terms. The practical friction for sponsors is tri-lateral Swissmedic + EMA + FDA coordination on programmes targeting multiple regions — routine for Swiss big pharma but worth planning early for smaller operators.
Methodology note
Sources and interpretation
Sources: verified Memel Biotech directory entries for every Swiss operator, official company disclosures, Swissmedic regulatory materials, and editorial comparison against Nordic, German, and Baltic directory coverage. The directory entry for each operator links to the authoritative company sources.
Disclaimer
Use limits
This brief is an editorial map of visible Swiss biotech and pharma activity in 2026. It does not rank operators or disclose non-public capacity information — sponsors should verify directly with each operator before engagement.
Primary sources
Source list
Related pages
Related directory records
Briefs
Continue through related topics.
A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.